The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats

Journal of Lipid Research

Volumn 51, Issue 9, 2010, Pages 2695-2705

  Dai, Lijun ^a   Datta, Geeta ^b   Zhang, Zhenghao ^b   Gupta, Himanshu ^b   Patel, Rakesh ^c   Honavar, Jaideep ^b   Modi, Sarika ^b   Wyss, J Michael ^d   Palgunachari, Mayakonda ^b   Anantharamaiah, G M ^b,e   Roger White, C ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Lipopolysaccharide; Nitric oxide synthase 2; Vascular function

Indexed keywords

ACETYLASPARTYLTRYPTOPHANYLPHENYLALANYLLYSYLALANYLPHENYLALANYLTYROSYLASPARTYLLYSYLVALYLALANYLGLUTAMYLLYSYLPHENYLALANYLLYSYLGLUTAMYLALANYLPHENYLALANINE AMIDE; APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 MIMETIC PEPTIDE 4F; CARBON 14; ENDOTOXIN; HIGH DENSITY LIPOPROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; NITRIC OXIDE; PHENYLEPHRINE; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; ENDOTOXEMIA; EX VIVO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; METABOLITE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; UPREGULATION;

ANIMALS; APOLIPOPROTEIN A-I; BLOOD PRESSURE; BLOOD VESSELS; CHOLESTEROL, HDL; CYCLOOXYGENASE INHIBITORS; ENDOTOXEMIA; HEMODYNAMICS; HUMANS; INDOMETHACIN; LIPOPOLYSACCHARIDES; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITROBENZENES; PEPTIDES; PHENYLEPHRINE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; VASOCONSTRICTOR AGENTS;

EID: 77956843092     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M008086     Document Type: Article

References (57)

1. Angus, D. C., W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29: 1303-1310.
2. Tobias, P. S., R. I. Tapping, and J. A. Gegner. 1999. Endotoxin interactions with lipopolysaccharide-responsive cells. Clin. Infect. Dis. 28: 476-481.
3. Zhang, J., and S. Rivest. 2003. Is survival possible without arachidonate metabolites in the brain during systemic infection? News Physiol. Sci. 18: 137-142. (Pubitemid 37026101)
4. Guha, M., and N. Mackman. 2001. LPS induction of gene expression in human monocytes. Cell. Signal. 13: 85-94.
5. Bannerman, D. D., and S. E. Goldblum. 2003. Mechanisms of bacterial lipopolysaccharide-induced endothelial apoptosis. Am. J. Physiol. 284: L899-L914.
6. Opal, S. M., and T. Gluck. 2003. Endotoxin as a drug target. Crit. Care Med. 31: S57-S64.
7. Kalogeris, T. J., C. G. Kevil, F. S. Laroux, L. L. Coe, T. J. Phifer, and J. S. Alexander. 1999. Differential monocyte adhesion and adhesion molecule expression in venous and arterial endothelial cells. Am. J. Physiol. 276: L9-L19.
8. Danenberg, H. D., F. G. P. Welt, M. Walker, P. Seifert, G. S. Toegel, and E. R. Edelman. 2002. Systemic inflammation induced by lipopolysaccharide increases neointimal formation after balloon and stent injury in rabbits. Circulation. 105: 2917-2922.
9. Stoclet, J. C., M. C. Martinez, P. Ohlmann, S. Chasserot, C. Schott, A. L. Kleschyov, F. Schneider, and R. Andriantsitohaina. 1999. Induction of nitric oxide synthase and dual effects of nitric oxide and cyclooxygenase products in regulation of arterial contraction in human septic shock. Circulation. 100: 107-112.
10. Chauhan, S. D., G. Seggara, P. A. Vo, R. J. Macallister, A. J. Hobbs, and A. Ahluwalia. 2003. Protection against lipopolysaccharide-induced endothelial dysfunction in resistance and conduit vasculature of iNOS knockout mice. FASEB J. 17: 773-775.
11. Höcherl, K., F. Dreher, A. Kurtz, and M. Bucher. 2002. Cyclo-oxygenase-2 inhibition attenuates lipopolysaccharide-induced cardiovascular failure. Hypertension. 40: 947-953. (Pubitemid 35434921)
12. Gunnett, C. A., Y. Chu, D. D. Heistad, A. Loihl, and F. M. Faraci. 1998. Vascular effects of LPS in mice deficient in expression of the gene for inducible nitric oxide synthase. Am. J. Physiol. 275: H416-H421.
13. d'Emmanuele di Villa Bianca, R., L. Lippolis, G. Autore, A. Popolo, S. Marzocco, L. Sorrentino, A. Pinto, and R. Sorrentino. 2003. Dexamethasone improves vascular hyporeactivity induced by LPS in vivo by modulating ATP-sensitive potassium channels activity. Br. J. Pharmacol. 140: 91-96.
14. Ozturk, O. H., A. Cetin, S. S. Ozdem, N. Uysal, U. A. Kayisli, U. K. Senturk, and A. Yesilkaya. 2006. Plasma levels of nitrites, PGF1-alpha, and nitrotyrosine in LPS-treated rats: functional and histochemical implications in aorta. J. Physiol. Biochem. 62: 27-34.
15. Bone, R. C. 1993. Gram-negative sepsis: a dilemma of modern medicine. Clin. Microbiol. Rev. 6: 57-68.
16. Hotchkiss, R. S., and I. E. Karl. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348: 138-150.
17. Wheeler, A. P., and G. R. Bernard. 1999. Treating patients with severe sepsis. N. Engl. J. Med. 340: 207-214.
18. Warnholtz, A., S. Genth-Zotz, and T. Munzel. 2005. Should treatment of sepsis include statins? Circulation. 111: 1735-1737.
19. Berbee, J. F. P., L. M. Havekes, and P. C. N. Rensen. 2005. Apolipoproteins modulate the inflammatory response to lipopolysaccharide. J. Endotoxin Res. 11: 97-103.
20. Feingold, K. R., J. L. Funk, A. H. Moser, J. K. Shigenaga, J. H. Rapp, and C. Grunfeld. 1995. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect. Immun. 63: 2041-2046.
21. Wurfel, M. M., and S. D. Wright. 1997. Lipopolysaccharide-binding protein and soluble CD14 transfer lipopolysaccharide to phospholipids bilayers. J. Immunol. 158: 3925-3934.
22. van Leeuwen, H. J., E. C. J. M. Heezius, G. M. Dallinga, J. A. G. van Strijp, J. Verhoef, and K. P. M. van Kessel. 2003. Lipoprotein metabolism in patients with severe sepsis. Crit. Care Med. 31: 1359-1366.
23. Wu, A., C. J. Hinds, and C. Thiemermann. 2004. High density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock. 21: 210-221.
24. Levine, D. M., T. S. Parker, T. M. Donnelly, A. Walsh, and A. L. Rubin. 1993. In vivo protection against endotoxin by plasma high density lipoprotein. Proc. Natl. Acad. Sci. USA. 90: 12040-12044.
25. Cohen, J. 2002. The immunopathogenesis of sepsis. Nature. 420: 885-891.
26. Abraham, E. 2001. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med. 25: 556-566. (Pubitemid 29312588)
27. Ulloa, L., M. Brunner, L. Ramos, and E. A. Deitch. 2009. Scientific and clinical challenges in sepsis. Curr. Pharm. Des. 15: 1918-1935.
28. Bernard, G. R., J. L. Vincent, P. F. Laterre, S. P. LaRosa, J. F. Dhainaut, A. Lopez-Rodriguez, J. S. Steingrub, G. E. Garber, J. D. Helterbrand, E. W. Ely, et al. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344: 699-709.
29. Nadel, S., B. Goldstein, M. D. Williams, H. Dalton, M. Peters, W. L. Macias, S. A. Abd-Allah, H. Levy, R. Angle, D. Wang, et al. 2007. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet. 369: 836-843.
30. White, C. R., G. Datta, P. Mochon, Z. Zhang, O. Kelly, C. Curcio, D. Parks, M. Palgunachari, S. Handattu, H. Gupta, et al. 2009. Vasculoprotective effects of apolipoprotein mimetic peptides: an evolving paradigm in HDL therapy. Vasc. Dis. Prev. 6: 122-130.
31. Gupta, H., L. Dai, G. Datta, D. W. Garber, H. Grenett, Y. Li, V. Mishra, M. N. Palgunachari, S. Handattu, S. H. Gianturco, et al. 2005. Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein A-I mimetic peptide. Circ. Res. 97: 236-243.
32. Datta, G., M. Chaddha, S. Hama, M. Navab, A. M. Fogelman, D. W. Garber, V. K. Mishra, R. M. Epand, R. F. Epand, S. Lund-Katz, et al. 2001. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J. Lipid Res. 42: 1096-1104.
33. Jones, M. K., G. M. Anantharamaiah, and J. P. Segrest. 1992. Computer programs to identify and classify amphipathic α-helical domains. J. Lipid Res. 33: 287-296.
34. Lund-Katz, S., G. M. Anantharamaiah, Y. V. Venkatachalapathi, J. P. Segrest, and M. C. Phillips. 1990. Nuclear magnetic resonance investigation of interactions of an amphipathic α-helix forming peptide of an apolipoprotein class. J. Biol. Chem. 265: 12217-12223.
35. Handattu, S. P., D. W. Garber, D. C. Horn, D. W. Hughes, B. Berno, A. D. Bain, V. K. Mishra, M. N. Palgunachari, G. Datta, G. M. Anantharamaiah, et al. 2007. ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers. J. Biol. Chem. 282: 1980-1988.
36. Bloedon, L. T., R. Dunbar, D. Duffy, P. Pinell-Salles, R. Norris, B. J. DeGroot, R. Movva, M. Navab, A. M. Fogelman, and D. J. Rader. 2008. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res. 49: 1344-1352.
37. Rivera, C. A., and R. G. Thurman. 1998. Tips for measuring endotoxin in plasma. Alcohol. Clin. Exp. Res. 22: 2192-2194.
38. Hayashi, Y., M. Abe, A. Murai, N. Shimizu, I. Okamoto, T. Katsuragi, and K. Tanaka. 2005. Comparison of effects of nitric oxide sunthase (NOS) inhibitors on plasma nitrate.nitrite levels and tissue NOS activity in septic organs. Microbiol. Immunol. 49: 139-147.
39. Kahlke, V., M. Seidel, S. Stapela, K. Brötzmann, C. Schafmayer, and J. Schröder. 2004. Inhibition of cyclooxygenase-2 by NS-398 following hemorrhage and subsequent sepsis: no beneficial effects in either gender. Surg. Infect. (Larchmt). 5: 29-37.
40. Garber, D. W., Y. V. Venkatachalapathi, K. B. Gupta, J. Ibdah, M. C. Phillips, J. B. Hazelrig, J. P. Segrest, and G. M. Anantharamaiah. 1992. Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats: correlation with physical properties. Arterioscler. Thromb. 12: 886-894.
41. Hsu, D. Z., and M. Y. Liu. 2002. Sesame oil attenuates multiple organ failure and increases survival rate during endotoxemia in rats. Crit. Care Med. 30: 1859-1862.
42. Krishnagopalan, S., A. Kumar, J. E. Parrillo, and A. Kumar. 2002. Myocardial dysfunction in the patient with sepsis. Curr. Opin. Crit. Care. 8: 376-388.
43. Xuan, D., D. P. Nicolau, C. H. Nightingale, and R. Quintiliani. 2001. Circulating tumor necrosis factor-alpha production during the progression of rat endotoxic sepsis. Chemotherapy. 47: 194-202. (Pubitemid 32304652)
44. Navab, M., G. M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, G. Hough, A. Wagner, K. Nakamura, D. W. Garber, G. Datta, J. P. Segrest, et al. 2003. Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis. Curr. Opin. Invest. Drug. 4: 1100-1104.
45. Kitchens, R. L., P. A. Thompson, R. S. Munford, and G. E. O'Keefe. 2003. Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J. Lipid Res. 44: 2339-2348.
46. Garber, D. W., G. Datta, M. Chaddha, M. N. Palgunachari, S. Y. Hama, M. Navab, A. M. Fogelman, J. P. Segrest, and G. M. Anantharamaiah. 2001. A new synthetic class A amphipathic peptide analogue protects mice from diet induced atherosclerosis. J. Lipid Res. 42: 545-552.
47. Navab, M., G. M. Anantharamaiah, S. T. Reddy, B. J. van Lenten, G. Datta, D. Garber, and A. M. Fogelman. 2004. Human apolipoprotein A-I and A-I mimetic peptide: potential for atherosclerosis reversal. Curr. Opin. Lipidol. 15: 645-649.
48. Schildknecht, S., M. Bachschmid, A. Baumann, and V. Ullrich. 2004. COX-2 inhibitors selectively block prostacyclin synthesis in endotoxin-exposed vascular smooth muscle cells. FASEB J. 18: 757-759.
49. Vayssettes-Courchay, C., F. Bouysset, and T. J. Verbeuren. 2002. Involvement of COX and NOS induction in the sympatho-activation during sepsis. Auton. Neurosci. 98: 33-36.
50. Leach, M., L. C. Hamilton, A. Olbrich, G. M. Wray, and C. Thiemermann. 1998. Effects of inhibitors of the activity of cyclooxygenase-2 on the hypotension and multiple organ dysfunction caused by endotoxin: a comparison with dexamethasone. Br. J. Pharmacol. 124: 586-592.
51. Fox, G. A., N. A. M. Paterson, and D. G. McCormack. 1996. Cyclooxygenase inhibition and vascular reactivity in a rat model of hyperdynamic sepsis. J. Cardiovasc. Pharmacol. 28: 30-35.
52. Navab, M., G. M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, V. R. Grijalva, A. C. Wagner, J. S. Frank, G. Datta, D. Garber, et al. 2004. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 109: 3215-3220.
53. Pajkrt, D., J. E. Doran, F. Koster, P. G. Lerch, B. Arnet, T. van der Poll, J. W. ten Cate, and S. J. van Deventer. 1996. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J. Exp. Med. 184: 1601-1608.
54. Navab, M., G. M. Anantharamaiah, S. Hama, D. W. Garber, M. Chaddha, G. Hough, R. Lallone, and A. M. Fogelman. 2002. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 105: 290-292.
55. Wool, G. D., T. Vaisar, C. A. Reardon, and G. S. Getz. 2009. An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide. J. Lipid Res. 50: 1889-1900.
56. Navab, M., I. Shechter, G. M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, and A. M. Fogelman. 2010. Structure and function of HDL mimetics. Arterioscler. Thromb. Vasc. Biol. 30: 164-168.
57. Zhang, Z., G. Datta, Y. Zhang, A. P. Miller, P. Mochon, Y. F. Chen, J. Chatham, G. M. Anantharamaiah, and C. R. White. 2009. Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats. Am. J. Physiol. 297: H866-H873.